ANRESIS The Swiss Centre for Antibiotic Resistance

ANRESIS is a Swiss nationwide, representative surveillance system and research instrument for antibiotic resistance and consumption.

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

This account will be deactivated soon. To stay connected and get our news, please follow us on https://t.co/qqfd4OGb28

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

Carbapenem resistance in Enterobacterales, Pseudomonas aeruginosa and Acinetobacter spp. increased in hospital respiratory samples from 2007 to 2024, according to an ANRESIS study just published in Eurosurveillance.
https://t.co/8PL1ldBzqk

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

The best antibiotic is the antibiotic which is not prescribed. ANRESIS analyzed this special view on the Sentinella data and presented first insights at ESCMID Global 2026.
https://t.co/diIfIsuJxc

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

This article summarizes 20 years of ANRESIS—from data collection to the development of interactive tools (in German): https://t.co/RvzxJseByg

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

What does the AMR situation in India look like – and how is Switzerland connected? A compelling report by SRF’s Trendmagazine explores the global dynamics of antimicrobial resistance (in German). https://t.co/jr6ranLgtj

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

A new study based on ANRESIS data shows an association between antimicrobial consumption and C. difficile incidence in a Swiss medical centre. https://t.co/yilnr92cZb

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

ANRESIS participated in this year’s #ESCMID Global Congress, presenting research on outpatient antibiotic use (https://t.co/HKGE0XybCf), Candida infections (https://t.co/pybgvkAMCc), and nosocomial respiratory pathogens (https://t.co/I9KCSwktDr).

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

Our latest study on Pseudomonas aeruginosa bloodstream infections in Switzerland (2010-2022) reveals increasing incidence and antibiotic resistance. Notably, we observed a high incidence in elderly, while resistance rates were elevated in young patients. https://t.co/GAZeEd1aK5

[Universität Bern @unibern]

🦠 World #Antibiotic Awareness Week #WAAW: The India-specific version of the @ANRESIS Guide from #unibern provides an overview of #resistance situation in North and West India, laying the groundwork for greater awareness: https://t.co/hwjWMmAvFd.
@BAG_OFSP_UFSP

[BAG – OFSP – UFSP @BAG_OFSP_UFSP]

🗞️ Der neue Swiss Antibiotic Resistance Report 2024 (SARR) zeigt, dass der Einsatz von Antibiotika weiterhin rückläufig ist 👇
https://t.co/GwMTqHIQLe

#WAAW #AntimicrobialResistance

[BAG – OFSP – UFSP @BAG_OFSP_UFSP]

🗞️ Le nouveau Swiss Antibiotic Resistance Report 2024 (SARR) montre que l’utilisation d’antibiotiques continue de baisser 👇
https://t.co/vDXjH1yL4W

#WAAW #AntimicrobialResistance

[BAG – OFSP – UFSP @BAG_OFSP_UFSP]

🗞️ Il nuovo Swiss Antibiotic Resistance Report (SARR) 2024 rivela che l’uso di antibiotici è in continua diminuzione 👇
https://t.co/xdrBXlWGZn

#WAAW #AntimicrobialResistance

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

In a programme on Swiss radio SRF it was discussed why we should pay attention to global AMR trends and the situation in animals. With insights from ANRESIS. Tune in now! https://t.co/aqgLBY6bah
(German, SRF Wissenschaftsmagazin 28.9.24)

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

Antibiotic use also matters for C. difficile incidence rates. Learn more from the ANRESIS poster at the Joint Annual Meeting of SSI/SSM/SSHH 2024 in Bern. https://t.co/llEa5ps5TE

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

📰Read our latest study on how the COVID-19 pandemic affected ESCR E. coli and K. pneumoniae bloodstream infections in Switzerland.
https://t.co/yPoTM8dXme

[BAG – OFSP – UFSP @BAG_OFSP_UFSP]

🗞️ Antibiotikaresistenzen: Der Bundesrat hat den neuen #OneHealth-Aktionsplan 2024–2027 im Rahmen der Strategie Antibiotikaresistenzen Schweiz (StAR) verabschiedet. Dieser sieht einen kollektiven Ansatz vor @BLV_OSAV_USAV @CHblw @bafuCH
👇
https://t.co/vFCU5ejaiu

[BAG – OFSP – UFSP @BAG_OFSP_UFSP]

🗞️ Résistance antibiotique : le Conseil fédéral a adopté le nouveau plan d’action #OneHealth 2024-2027, dans le cadre de la Stratégie Antibiorésistance Suisse (StAR). Il propose une approche collective @BLV_OSAV_USAV @CHblw @bafuCH
👇
https://t.co/4ddueqaDFQ

[BAG – OFSP – UFSP @BAG_OFSP_UFSP]

🗞️ Resistenze agli antibiotici: il Consiglio federale ha adottato il nuovo piano d’azione #OneHealth 2024–2027 della Strategia nazionale contro le resistenze agli antibiotici (StAR), che propone un approccio collettivo tra @BLV_OSAV_USAV @CHblw @bafuCH
👇
https://t.co/naOapok8G6

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

ANRESIS contributed to posters during the 2024 congress @SGAIM_SSMIG including one presented by Sereina M. Graber and others on the contribution of the different prescribers to the overall outpatient antimicrobial consumption https://t.co/XFVvx1ZAYH. Congratulations on your work!

[ANRESIS The Swiss Centre for Antibiotic Resistance @anresis]

ANRESIS was present at this year's ESCMID Global congress with posters on the WHO target of 60% Access group antibiotics reached by Switzerland (https://t.co/l8sN5Xj0zi) and on extended-spectrum cephalosporin resistances during the COVID-19 pandemic (https://t.co/Im5YS1RK27).